+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood



Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood



Pediatric Hematology & Oncology 17(7): 527-540, October-November



Long-term leukemia survivors (46) underwent cardiac evaluation, including physical examination, ECG, exercise testing, and echocardiography. They were 2-17 years old at diagnosis and 5-23 years old after treatment. Thirty-four survivors received anthracyclines (AC) (mean 203 mg/m2), 12 of them had also alkylating agents (AA) and 12 had no AC. Exercise tolerance was bellow predicted values in 21 (48%) survivors and 21 survivors had ECG abnormalities, which were more frequent in those treated with AC. Concomitant AC with AA was correlated with prolonged isovolumic relaxation time (IVRT) and influenced significantly the volume of left atrium (p = .02). Sixteen (52%) survivors had IVRT gtoreq 90 ms. There were no significant differences in other parameters of diastolic or systolic function. Despite the lack of clinical symptoms in the survivors treated with lower doses of AC, subtile abnormalities in myocardial function were found, mainly manifest as abnormal diastolic function. Prolonged IVRT may be a sensitive indicator for early detection of AC cardiotoxicity.

(PDF emailed within 0-6 h: $19.90)

Accession: 010912119

Download citation: RISBibTeXText

PMID: 11033728

DOI: 10.1080/08880010050122799


Related references

Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer 48(7): 663-667, 2007

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. Journal of Cancer Survivorship 6(1): 95-101, 2012

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New England Journal of Medicine 324(12): 808-815, 1991

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 16(2): 545-550, 1998

Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 34(5): 395-397, 2012

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. Journal of Clinical Oncology 15(1): 61-68, 1997

Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: No long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Medical & Pediatric Oncology 35(1): 13-19, 2000

Early response to induction therapy and occult testicular leukemia otl at end therapy predict late relapse lr in childhood acute lymphoblastic leukemia all. Pediatric Research 21(4 PART 2): 302A, 1987

Late cardiac effects of doxorubicin in childhood acute lymphoblastic leukemia. Journal of the American College of Cardiology 11(2 SUPPL A): 135A, 1988

Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors. Turkish Journal of Haematology 2018, 2018

Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study. International Journal of Clinical Oncology 22(2): 387-396, 2016

Persistent presence of common acute lymphoblastic leukemia antigen positive cells in regenerating bone marrow after cessation of maintenance therapy in acute lymphoblastic leukemia of childhood. European Paediatric Haematology & Oncology 2(4): 217-219, 1985

Anthracycline cross-resistance pattern in childhood relapsed acute lymphoblastic leukemia. Blood 82(10 SUPPL 1): 54A, 1993

Late intensification therapy with high dose methotrexate in standard risk acute lymphoblastic leukemia in childhood. Proceedings of the American Association for Cancer Research Annual Meeting 30: 266, 1989

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 23(12): 2629-2636, 2005